We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.2B
AUM Growth
-$978M
Cap. Flow
-$700M
Cap. Flow %
-13.47%
Top 10 Hldgs %
44.11%
Holding
176
New
13
Increased
49
Reduced
69
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.9M
2
BRKR icon
Bruker
BRKR
+$21.3M
3
AMGN icon
Amgen
AMGN
+$19M
4
EHC icon
Encompass Health
EHC
+$16.6M
5
THC icon
Tenet Healthcare
THC
+$15.6M

Top Sells

Rank Stock Value
1
OPCH icon
Option Care Health
OPCH
+$51.8M
2
EPIX
ESSA Pharma
EPIX
+$47.8M
3
EXAS
Exact Sciences
EXAS
+$47M
4
CDNA icon
CareDx
CDNA
+$43.1M
5
EXEL icon
Exelixis
EXEL
+$41.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Industrials 0.04%
3 Communication Services 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
151
Kura Oncology
KURA
$922M
$118K ﹤0.01%
13,600
– –
MRNA icon
152
CALL
Moderna
MRNA
$21.5B
$110K ﹤0.01%
+150
New +$7.17K
ORCL icon
153
Oracle
ORCL
$331B
$109K ﹤0.01%
654
+30
+5% +$5.33K
A icon
154
Agilent Technologies
A
$39.1B
$108K ﹤0.01%
806
+37
+5% +$5.07K
NVDA icon
155
NVIDIA
NVDA
$5.01T
$101K ﹤0.01%
751
+35
+5% +$4.82K
AUTL
156
Autolus Therapeutics
AUTL
$386M
$97.5K ﹤0.01%
41,500
– –
MSFT icon
157
Microsoft
MSFT
$2.84T
$85.6K ﹤0.01%
203
+9
+5% +$3.83K
QCOM icon
158
Qualcomm
QCOM
$176B
$68.7K ﹤0.01%
447
+20
+5% +$3.27K
MTD icon
159
Mettler-Toledo International
MTD
$26.8B
$51.4K ﹤0.01%
42
+1
+2% +$1.3K
LH icon
160
Labcorp
LH
$24.3B
$49.5K ﹤0.01%
216
+10
+5% +$2.29K
TEM
161
Tempus AI
TEM
$7.69B
$8K ﹤0.01%
237
-279
-54% -$13.8K
APLS
162
DELISTED
Apellis Pharmaceuticals
APLS
– –
-19,046
Closed -$549K
CRSP icon
163
CRISPR Therapeutics
CRSP
$4.58B
– –
-610,000
Closed -$28.7M
EPIX
164
DELISTED
ESSA Pharma
EPIX
– –
-7,879,583
Closed -$47.8M
EXEL icon
165
Exelixis
EXEL
$13.9B
– –
-1,600,000
Closed -$41.5M
GBIO
166
DELISTED
Generation Bio
GBIO
– –
-391,886
Closed -$9.68M
HCM icon
167
HUTCHMED
HCM
$1.89B
– –
-24,015
Closed -$469K
IDYA icon
168
IDEAYA Biosciences
IDYA
$3.41B
– –
-7,200
Closed -$228K
NKE icon
169
Nike
NKE
$61.9B
– –
-3,500
Closed -$309K
OABI icon
170
OmniAb
OABI
$294M
– –
-11,456
Closed -$48.5K
OPCH icon
171
Option Care Health
OPCH
$3.4B
– –
-1,654,878
Closed -$51.8M
RCKT icon
172
Rocket Pharmaceuticals
RCKT
$348M
– –
-9,300
Closed -$172K
SMMT icon
173
CALL
Summit Therapeutics
SMMT
$10.9B
– –
-10,000
Closed -$219K
SNY icon
174
Sanofi
SNY
$104B
– –
-15,109
Closed -$871K
VTRS icon
175
Viatris
VTRS
$20.1B
– –
-39,283
Closed -$456K
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2024 Portfolio in Review

As of Q4 2024, Bellevue Group held 176 positions worth $5.2B, down 16% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Bellevue Group withdrew a net $700M in Q4 2024, closing 15 positions and reducing 69 holdings. Its most notable exit was Option Care Health, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Bruker worth $21.1M.

  • Bellevue Group's largest Q4 2024 buy was Bruker: 359,588 shares worth $21.1M.
  • Bellevue Group added most to Merck in Q4 2024, an estimated $22.9M increase.
  • Bellevue Group's biggest Q4 2024 reduction was Exact Sciences, cutting an estimated $47M.
  • Bellevue Group fully exited Option Care Health in Q4 2024, selling an estimated $51.8M.
  • Bellevue Group's ten largest holdings make up 44% of its $5.2B portfolio in Q4 2024.
  • Bellevue Group opened 13 new positions and closed 15 in Q4 2024.
  • Bellevue Group's portfolio value fell 16% quarter-over-quarter to $5.2B.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.